因美纳：六赴进博，加速全球创新引进，扎根本土生态

Core Insights - The 8th China International Import Expo (CIIE) will be held from November 5 to 10, 2025, in Shanghai, featuring participation from 155 countries and regions, with over 4,108 foreign enterprises exhibiting, marking a record exhibition area of over 430,000 square meters [1] - The CIIE has successfully showcased China's vast market potential and commitment to openness, contributing positively to global economic development [1] - The life sciences sector in China is experiencing significant innovation, particularly in precision medicine and biopharmaceuticals, reshaping healthcare services [1] - Illumina, a leader in gene sequencing and chip technology, is participating in the CIIE for the sixth time, focusing on innovative solutions in the medical device and healthcare sector [1] Company Strategy - Illumina is celebrating its 20th anniversary in China, emphasizing its commitment to localization and bringing innovative solutions to the Chinese market [2] - The company aims to enhance local procurement and manufacturing, marking a new phase in its localization strategy [2][3] - Illumina's strategy aligns with China's "14th Five-Year Plan," which promotes high-quality development in the biopharmaceutical industry and emphasizes the importance of local manufacturing and supply chain resilience [3][4] Product Innovations - Illumina introduced two cutting-edge solutions at the CIIE, including the Illumina Protein Prep solution and a new five-base solution, both aimed at advancing drug discovery and precision medicine [8][9] - The NovaSeq 6000Dx-CN-BG, a high-throughput sequencing instrument, has received regulatory approval in China, enhancing its clinical applications in oncology and rare disease detection [6][11] - The new five-base solution addresses limitations in traditional sequencing methods, allowing for simultaneous detection of genetic markers, thus improving efficiency in clinical research [9] Market Positioning - Illumina's localization efforts are supported by strategic partnerships with local companies to strengthen supply chain resilience and enhance local manufacturing capabilities [5][6] - The company is committed to providing innovative solutions that meet international standards, facilitating the integration of Chinese research with global practices [12][13] - Illumina's ongoing investments in R&D, projected at nearly $1 billion for 2024, reflect its dedication to supporting China's life sciences innovation [11][14]